What is the 13F Pro Quality Score for VNDA?

13F Pro ranks Vanda Pharmaceuticals Inc. (VNDA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VNDA's current score at https://13fpro.ai/research/VNDA (free sign-up required for the full ranking).

Which hedge funds own the most VNDA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VNDA include BlackRock,, RENAISSANCE TECHNOLOGIES, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/VNDA as soon as new 13F filings post.

Where does 13F Pro source VNDA data?

All Vanda Pharmaceuticals Inc. fundamentals and ownership data come directly from SEC EDGAR. Vanda Pharmaceuticals Inc. files with the SEC under CIK 1347178. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VNDA in?

Vanda Pharmaceuticals Inc. (VNDA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VNDA research updated on 13F Pro?

VNDA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vanda Pharmaceuticals Inc.(VNDA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1347178 VNDA stock profile & AI dashboard →

13F Pro Quality Score

24.8/100

Rank #2,574 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

47.2/100

Profitability

9.3/100

Balance Sheet

8.8/100

Earnings Quality

30.0/100

Free Cash Flow

8.2/100

Institutional Flow

86.1/100

Revenue Scale

25.0/100

Dilution Risk

27.7/100

VNDA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Vanda Pharmaceuticals Inc. (VNDA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VNDA at 24.8/100 on a 32-signal composite quality model, placing it at rank #2,574 of 2,879 stocks — the bottom half of the AI-ranked universe. VNDA scores in the top quartile across institutional flow (86.1). Areas of concern include free cash flow (8.2) and balance sheet strength (8.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Vanda Pharmaceuticals Inc. reports quarterly revenue of $51.7M, net income of $-48.6M, free cash flow of $-50.4M. Top institutional holders of VNDA by reported 13-F value include BlackRock,, RENAISSANCE TECHNOLOGIES, STATE STREET, based on the most recent SEC filings. VNDA trades on the Nasdaq exchange and files with the SEC under CIK 1347178. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VNDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vanda Pharmaceuticals Inc. directly from SEC EDGAR. Vanda Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 8 and 59 since 2021, currently 24.8 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Vanda Pharmaceuticals Inc.

Quirks, history, and lore behind VNDA — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company · listed on Nasdaq · headquartered in Washington, DC · focused on central nervous system and other specialty disorders.
2
The Numbers
Annual revenue in the range of $200–250 million — modest by pharma standards — with a lean commercial operation built around a handful of approved drugs rather than a sprawling pipeline.
3
The History
Founded in the early 2000s by scientists with roots in NIH research, it built its identity around repurposing and studying drugs that larger companies had largely overlooked.
4
The Secret
The company has become a specialist in Non-24-Hour Sleep-Wake Disorder — a rare circadian rhythm condition particularly prevalent among the totally blind — a niche almost no one else pursued.
5
The Lore
Its lead product Hetlioz was the first FDA-approved treatment for Non-24, and the company has fought high-profile legal battles to defend its orphan drug exclusivity against generic challengers.
6
The Giveaway
A DC-based biopharma that owns Hetlioz for sleep disorders and Fanapt for schizophrenia — two very different conditions, one very focused specialty pharma niche-hunter.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$51.7M

Net Income

Q1 2026

$-48.6M

Free Cash Flow

Q1 2026

$-50.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+12.2% YoY

$216.1MFY 2025

FY19 $227.2MFY22 $254.4MFY23 $192.6MFY25 $216.1M

Net Income

-8919.0% YoY

$-220.5MFY 2025

FY19 $115.6MFY22 $6.3MFY23 $2.5MFY25 $-220.5M

Operating Income

-983.5% YoY

$-151.2MFY 2025

FY19 $22.8MFY22 $6.3MFY23 $-14.0MFY25 $-151.2M

EPS (Diluted)

-9450.0% YoY

$-3.74FY 2025

FY19 $2.11FY22 $0.11FY23 $0.04FY25 $-3.74

Total Assets

-24.6% YoY

$488.9MFY 2025

FY19 $483.7MFY22 $634.2MFY23 $648.4MFY25 $488.9M

Op. Cash Flow

-954.9% YoY

$-109.4MFY 2025

FY19 $45.9MFY22 $32.0MFY23 $12.8MFY25 $-109.4M

Metric	FY 2025	FY 2023	FY 2022	FY 2019	FY 2018	FY 2017
Revenue	$216.1M +12.2%	$192.6M -24.3%	$254.4M +12.0%	$227.2M +17.6%	$193.1M +17.0%	$165.1M
Net Income	$-220.5M -8919.0%	$2.5M -60.2%	$6.3M -94.6%	$115.6M +358.4%	$25.2M +261.9%	$-15.6M
Operating Income	$-151.2M -983.5%	$-14.0M -320.4%	$6.3M -72.3%	$22.8M +4.9%	$21.7M +228.6%	$-16.9M
EPS (Diluted)	$-3.74 -9450.0%	$0.04 -63.6%	$0.11 -94.8%	$2.11 +339.6%	$0.48 +237.1%	$-0.35
Total Assets	$488.9M -24.6%	$648.4M +2.2%	$634.2M +31.1%	$483.7M +45.7%	$332.1M +61.7%	$205.4M
Operating Cash Flow	$-109.4M -954.9%	$12.8M -60.0%	$32.0M -30.4%	$45.9M +53.2%	$30.0M +1612.2%	$-2.0M

AI Insight: VNDA Ratio Trends

Vanda's profitability has collapsed, with Q1 2026 operating margin deteriorating to -97.1% — the worst single quarter in the dataset.

• Operating margin worsened sharply from -19.3% in Q4 2024 to -97.1% in Q1 2026, signaling a structural breakdown in earnings power.

• ROIC plunged from -7.6% in Q4 2024 to -71.5% in Q1 2026, reflecting deeply negative returns on invested capital.

• Net profit margin improved modestly from -58.9% in Q1 2025 to -40.2% in Q3 2025 before data gaps obscure Q4 2025.

• ROE collapsed to -172.6% in Q4 2025 before partially recovering to -69.2% in Q1 2026, suggesting equity base erosion.

⚠ Q1 2026 operating margin hit -97.1%, the worst in the dataset — monitor whether Q2 2026 shows any stabilization.

⚠ NPM and ROA data gaps in Q4 2025 limit visibility; any one-off charges driving Q4 ROE of -172.6% warrant scrutiny.

⚠ Debt/equity data is absent across all periods; undisclosed leverage changes could amplify downside risk.

Get alerted when VNDA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vanda Pharmaceuticals Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VNDA

BlackRock, Inc.
$50.3M7,275,988 sh
RENAISSANCE TECHNOLOGIES LLC
$26.0M3,759,559 sh
STATE STREET CORP
$20.8M3,015,562 sh
AIGH Capital Management LLC
$19.0M2,750,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.1M2,481,491 sh
MILLENNIUM MANAGEMENT LLC
$13.0M1,881,001 sh
DIMENSIONAL FUND ADVISORS LP
$12.2M1,771,593 sh
AQR CAPITAL MANAGEMENT LLC
$11.1M1,603,576 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.0M1,442,965 sh
TWO SIGMA INVESTMENTS, LP
$9.7M1,398,201 sh

Fund	Value	Shares
BlackRock, Inc.	$50.3M	7,275,988
RENAISSANCE TECHNOLOGIES LLC	$26.0M	3,759,559
STATE STREET CORP	$20.8M	3,015,562
AIGH Capital Management LLC	$19.0M	2,750,000
VANGUARD CAPITAL MANAGEMENT LLC	$17.1M	2,481,491
MILLENNIUM MANAGEMENT LLC	$13.0M	1,881,001
DIMENSIONAL FUND ADVISORS LP	$12.2M	1,771,593
AQR CAPITAL MANAGEMENT LLC	$11.1M	1,603,576
GEODE CAPITAL MANAGEMENT, LLC	$10.0M	1,442,965
TWO SIGMA INVESTMENTS, LP	$9.7M	1,398,201

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VNDA on your watchlist

Track score changes the day Vanda Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VNDA a good stock to buy?

13F Pro's AI-powered analysis of Vanda Pharmaceuticals Inc. (VNDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VNDA are available on the VNDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VNDA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VNDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vanda Pharmaceuticals Inc.'s investment landscape.